These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18400075)

  • 1. The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing first-line treatment regimen selection.
    Huang HY; Daar ES; Sax PE; Young B; Cook P; Benson P; Cohen C; Scribner A; Hu H
    HIV Med; 2008 May; 9(5):285-93. PubMed ID: 18400075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
    Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
    Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
    Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
    Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters.
    Corvasce S; Violin M; Romano L; Razzolini F; Vicenti I; Galli A; Duca P; Caramma I; Balotta C; Zazzi M
    Antivir Ther; 2006; 11(3):329-34. PubMed ID: 16759049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali.
    Derache A; Traore O; Koita V; Sylla A; Tubiana R; Simon A; Canestri A; Carcelain G; Katlama C; Calvez V; Cisse M; Marcelin AG
    Antivir Ther; 2007; 12(1):123-9. PubMed ID: 17503757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium.
    Van Vaerenbergh K; Debaisieux L; De Cabooter N; Declercq C; Desmet K; Fransen K; Maes B; Marissens D; Miller K; Muyldermans G; Sprecher S; Stuyver L; Vaira D; Verhofstede C; Zissis G; Van Ranst M; De Clercq E; Desmyter J; Vandamme AM
    Antivir Ther; 2001 Mar; 6(1):63-70. PubMed ID: 11417763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes.
    SPREAD programme
    AIDS; 2008 Mar; 22(5):625-35. PubMed ID: 18317004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon.
    Vergne L; Diagbouga S; Kouanfack C; Aghokeng A; Butel C; Laurent C; Noumssi N; Tardy M; Sawadogo A; Drabo J; Hien H; Zekeng L; Delaporte E; Peeters M
    Antivir Ther; 2006; 11(5):575-9. PubMed ID: 16964825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey.
    Yerly S; von Wyl V; Ledergerber B; Böni J; Schüpbach J; Bürgisser P; Klimkait T; Rickenbach M; Kaiser L; Günthard HF; Perrin L;
    AIDS; 2007 Oct; 21(16):2223-9. PubMed ID: 18090050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
    Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
    Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: a French nationwide study.
    Masquelier B; Costagliola D; Schmuck A; Cottalorda J; Schneider V; Izopet J; Calvez V; Descamps D; Poggi C; Brun-Vézinet F;
    J Med Virol; 2005 Aug; 76(4):441-6. PubMed ID: 15977249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral drug resistance among antiretroviral-naïve persons with recent HIV infection in Thailand.
    Apisarnthanarak A; Jirayasethpong T; Sa-nguansilp C; Thongprapai H; Kittihanukul C; Kamudamas A; Tungsathapornpong A; Mundy LM
    HIV Med; 2008 May; 9(5):322-5. PubMed ID: 18400079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.